# A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

> **NCT03789604** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CStone Pharmaceuticals** · enrollment: 479 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** CS1001 monoclonal antibody
- **BIOLOGICAL:** CS1001 placebo

## Key facts

- **NCT ID:** NCT03789604
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-13
- **Primary completion:** 2023-05-15
- **Final completion:** 2027-06-30
- **Target enrollment:** 479 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789604, "A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03789604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*